Open Label Continuation Study in Moderate to Severe Psoriasis

NCT00626002 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2301

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: ABT-874

Sponsor

AbbVie (prior sponsor, Abbott)